VERAXA Biotech AG (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.
The company said its BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate and T-cell engager pipelines, reinforcing its long-term strategy to develop next-generation oncology therapeutics.
This patent expansion is significant as it strengthens VERAXA's competitive position in the rapidly evolving field of cancer immunotherapy. By securing broad intellectual property protection for its BiTAC platforms and related technologies, the company is building a moat around its proprietary approaches to bispecific T-cell engagers and antibody-drug conjugates. The extended protection through 2047 provides long-term exclusivity, which is crucial for attracting partnerships and investment to advance its pipeline into clinical development.
The implications of this announcement are multifaceted. For investors, a robust patent portfolio reduces technological risk and enhances the company's valuation. For the broader oncology field, VERAXA's technologies could lead to safer and more effective treatments by precisely targeting cancer cells while sparing healthy tissue. The company's focus on quality-by-design principles and its foundation on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL) underscore its commitment to rigorous science.
VERAXA's BiTAC platform represents a novel approach to cancer therapy, aiming to overcome limitations of conventional T-cell engagers and ADCs. By requiring multiple tumor-associated targets for activation, BiTACs may reduce off-target toxicities, a common challenge in immunotherapy. The proprietary conjugation and linker technologies further enhance the therapeutic window and manufacturing feasibility.
With over 50 granted patents and pending applications, VERAXA is positioning itself as a leader in next-generation antibody-based therapeutics. The company's strategy to protect its innovations globally ensures that it can capitalize on its discoveries in major pharmaceutical markets. As the pipeline advances, the strength of its IP will be a key factor in its ability to bring new treatments to patients.
For more information, the full press release is available at https://ibn.fm/BqhFS.
